Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Amortization of Deferred Charges of $454000.0 for Q1 2026, up 4.85% year-over-year from $433000.0 in Q1 2025, and up 4.13% quarter-over-quarter from $436000.0 in Q4 2025.
Powered by 
Analysis
Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $454000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 4.85% year-over-year to $454000.0; the TTM figure through Mar 2026 stood at $1.8 million (up 4.76% YoY), while the FY2025 annual figure was $1.7 million, up 4.7% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $454000.0, up from $436000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $454000.0 in Q1 2026, with the low at -$101000.0 in Q2 2022.
- The 5-year median for Amortization of Deferred Charges is $415000.0 (2024), against an average of $355071.4.
- The sharpest annual moves came in 2022 and 2023: Amortization of Deferred Charges tumbled 205.21% in 2022, then soared 403.96% in 2023.
- Mirum Pharmaceuticals' Amortization of Deferred Charges stood at -$101000.0 in 2022, then jumped by 495.05% to $399000.0 in 2023, then increased by 4.26% to $416000.0 in 2024, then increased by 4.81% to $436000.0 in 2025, then rose by 4.13% to $454000.0 in 2026.
- Business Quant data shows MIRM's Amortization of Deferred Charges at $454000.0 in Q1 2026, $436000.0 in Q4 2025, and $443000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mirum Pharmaceuticals | 6.40 Bn | 5.96 Bn | 145.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 658,000.00 |
| Mar 31, 2026 | 454,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Sep 30, 2025 | 443,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 433,000.00 |
| Dec 31, 2024 | 416,000.00 |
| Sep 30, 2024 | 424,000.00 |
| Jun 30, 2024 | 407,000.00 |
| Mar 31, 2024 | 414,000.00 |
| Dec 31, 2023 | 399,000.00 |
| Sep 30, 2023 | 411,000.00 |
| Jun 30, 2023 | 307,000.00 |
| Dec 31, 2021 | -285,000.00 |
| Sep 30, 2021 | 94,000.00 |
| Jun 30, 2021 | 96,000.00 |
| Mar 31, 2021 | 95,000.00 |
| Dec 31, 2020 | 80,000.00 |
| Sep 30, 2020 | 78,000.00 |
| Jun 30, 2020 | 77,000.00 |